Lifecore Biomedical (LFCR) Expected to Release Quarterly Earnings on Wednesday

Lifecore Biomedical (NASDAQ:LFCR) is expected to be posting its resultson Wednesday, August 5th. Analysts expect the company to post earnings of ($0.2175) per share and revenue of $33.1320 million for the quarter.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.14). The company had revenue of $23.19 million for the quarter, compared to the consensus estimate of $25.96 million. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of NASDAQ:LFCR opened at $4.39 on Wednesday. Lifecore Biomedical has a one year low of $3.63 and a one year high of $8.98. The company has a market cap of $164.67 million, a price-to-earnings ratio of -4.67 and a beta of 1.06. The firm has a 50 day simple moving average of $5.09 and a 200 day simple moving average of $5.75.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LFCR shares. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings lowered Lifecore Biomedical from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Barrington Research boosted their price target on Lifecore Biomedical from $6.00 to $6.50 and gave the stock an “outperform” rating in a report on Tuesday, June 16th. Finally, Zacks Research lowered shares of Lifecore Biomedical from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $6.50.

Institutional Trading of Lifecore Biomedical

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares during the period. BNP Paribas Financial Markets grew its position in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after buying an additional 2,786 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Lifecore Biomedical by 20.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after buying an additional 2,826 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Lifecore Biomedical by 28.4% in the fourth quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock valued at $132,000 after buying an additional 3,574 shares during the period. Finally, Quarry LP acquired a new stake in shares of Lifecore Biomedical in the third quarter valued at about $28,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.